TherapeuticsMD Inc
NASDAQ:TXMD
TherapeuticsMD Inc
NASDAQ:TXMD
Price:
1.96 USD
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
TXMD
stock under the Base Case scenario is
2.46
USD.
Compared to the current market price of 1.96 USD,
TherapeuticsMD Inc
is
Undervalued by 20%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TXMD
Relative Value
Base Case
2.46
USD
Undervaluation 20%
Valuation Multiples
Multiples Across Competitors
TXMD Competitors Multiples
TherapeuticsMD Inc Competitors
TherapeuticsMD Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
TherapeuticsMD Inc
NASDAQ:TXMD
|
22.6m USD | 17.4 | -2.2 | -2.4 | -2.1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
739.2B USD | 20.6 | 120.4 | 59 | 67.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.3 | 44.5 | 33.2 | 36.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.9B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.2B USD | 5.4 | 143.2 | 35.7 | 58.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
190.8B GBP | 5 | 37.7 | 174.5 | 278.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
177B CHF | 3 | 15.4 | 8.8 | 10.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
177.2B CHF | 3.3 | 11.1 | 8.5 | 12.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.8 | -507.4 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
